MS417, a BET inhibitor derived from JQ1, specifically targets the interaction between BRD4 and the acetylated p65/RelA subunit of the transcription factor NF-kB and has potent anti-inflammatory effects in a mouse model of HIV-associated kidney disease [78]. Here, RELA is linked to kidney disorder.